MA46972A - Forme polymorphe de sépiaptérine - Google Patents

Forme polymorphe de sépiaptérine

Info

Publication number
MA46972A
MA46972A MA046972A MA46972A MA46972A MA 46972 A MA46972 A MA 46972A MA 046972 A MA046972 A MA 046972A MA 46972 A MA46972 A MA 46972A MA 46972 A MA46972 A MA 46972A
Authority
MA
Morocco
Prior art keywords
sepiapterin
polymorphic form
polymorphic
Prior art date
Application number
MA046972A
Other languages
English (en)
Inventor
Kaito Kishimoto
Taichi Komoda
Daniel E Levy
Takayoshi Matsumoto
Shunichi Murata
Yuichi Shiro
Hiroshi Yoshino
Original Assignee
Censa Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Censa Pharmaceuticals Inc filed Critical Censa Pharmaceuticals Inc
Publication of MA46972A publication Critical patent/MA46972A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MA046972A 2016-11-29 2017-11-28 Forme polymorphe de sépiaptérine MA46972A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662427686P 2016-11-29 2016-11-29

Publications (1)

Publication Number Publication Date
MA46972A true MA46972A (fr) 2019-10-09

Family

ID=62241955

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046972A MA46972A (fr) 2016-11-29 2017-11-28 Forme polymorphe de sépiaptérine

Country Status (8)

Country Link
US (2) US11130760B2 (fr)
EP (1) EP3548487A4 (fr)
JP (1) JP7148532B2 (fr)
CN (1) CN110312721A (fr)
CA (1) CA3043499A1 (fr)
MA (1) MA46972A (fr)
MX (1) MX391156B (fr)
WO (1) WO2018102314A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2562176B1 (fr) 2010-04-22 2018-08-15 Nihon University Agent médicinal et boisson/aliment pour prévenir un dysfonctionnement cérébral et améliorer ses symptômes
CN110312721A (zh) 2016-11-29 2019-10-08 显莎制药公司 墨蝶呤的多晶型物
EP3548497A4 (fr) 2016-11-29 2020-09-02 Censa Pharmaceuticals Inc. Polymorphes de sépiaptérine et leurs sels
EP3675863A4 (fr) 2017-09-01 2021-01-27 PTC Therapeutics MP, Inc. Composition pharmaceutique comprenant de la sépiaptérine et ses utilisations
EP3807279B1 (fr) * 2018-05-30 2025-12-31 PTC Therapeutics MP, Inc. Sels pharmaceutiquement acceptables de sépiaptérine avec une stabilité améliorée
BR112020024329A2 (pt) 2018-05-30 2021-02-23 Ptc Therapeutics Mp, Inc. composições e métodos para aumentar exposição de plasma de tetra-hidrobiopterin
MD3801536T2 (ro) 2018-05-30 2024-11-30 Ptc Therapeutics Mp Inc Administrarea sepiapterinei fără alimente pentru utilizare într-o metodă de creștere a expunerii plasmatice a sepiapterinei
FI4009978T3 (fi) 2019-08-05 2024-11-01 Ptc Therapeutics Mp Inc Sepiapteriiinin ja sen metaboliittien käyttö säteilyaltistuksen hoitoon
US20220362249A1 (en) 2019-09-25 2022-11-17 Ptc Therapeutics Mp, Inc. Methods for treating hyperphenylalaninemia
US20230110351A1 (en) 2020-01-24 2023-04-13 Ptc Therapeutics Mp, Inc. Methods for treating parkinson's disease with sepiapterin
AU2022221345A1 (en) 2021-02-09 2023-09-07 Ptc Therapeutics Mp, Inc. Methods for treating glioblastomas with sepiapterin
WO2022173823A1 (fr) 2021-02-09 2022-08-18 Ptc Therapeutics Mp, Inc. Procédés de traitement de la covid-19 avec de la sépiaptérine
US20250041305A1 (en) * 2021-09-29 2025-02-06 Ptc Therapeutics, Inc. Pharmaceutical composition of sepiapterin
CN117117299B (zh) * 2023-08-14 2024-12-06 国联汽车动力电池研究院有限责任公司 一种无机硫化物固体电解质及其制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5925323A (ja) * 1982-03-03 1984-02-09 鐘淵化学工業株式会社 プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤
US5753656A (en) 1994-08-05 1998-05-19 Suntory Limited Method for treating spinocerebellar degeneration
AU727445B2 (en) 1995-08-18 2000-12-14 Donald W Landry Detection of organic compounds through regulation of antibody-catalyzed reactions
US8188043B2 (en) 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
FR2859996B1 (fr) 2003-09-19 2006-02-03 Aventis Pharma Sa Solvat acetonique du dimethoxy docetaxel et son procede de preparation
US20070049599A1 (en) 2003-10-31 2007-03-01 Altana Pharma Ag Use of bh4 for the treatment of respiratory diseases
CA2678125C (fr) 2003-11-17 2014-10-14 Merck Eprova Ag Formes cristallines de dihydrochlorure de (6r)-l-erythro-tetrahydrobiopterine
JP5184783B2 (ja) 2003-11-17 2013-04-17 バイオマリン ファーマシューティカル インコーポレイテッド テトラヒドロビオプテリン、及びテトラヒドロビオプテリン類似体の製造方法
PL1708690T3 (pl) 2003-11-17 2017-01-31 Biomarin Pharmaceutical Inc. Leczenie fenyloketonurii za pomocą BH4
WO2006055511A2 (fr) 2004-11-17 2006-05-26 Biomarin Pharmaceutical Inc. Formule stable de comprimes
JP2008523090A (ja) 2004-12-08 2008-07-03 バイオマリン ファーマシューティカル インコーポレイテッド 新生児肺高血圧症の治療のための方法および組成物
KR101277074B1 (ko) 2005-04-28 2013-06-25 다이이찌 산쿄 가부시키가이샤 히드라존 유도체의 제조방법
US20080075666A1 (en) 2006-08-25 2008-03-27 Dudley Samuel C Jr Methods and compositions for treating diastolic dysfunction
HRP20220188T3 (hr) 2007-04-11 2022-04-29 Biomarin Pharmaceutical Inc. Načini primjene tetrahidrobiopterina, povezani pripravci i postupci mjerenja
UA103189C2 (ru) 2008-03-10 2013-09-25 Такеда Фармасьютикал Компани Лимитед Кристаллическая форма бензимидазольного соединения
ES2736730T3 (es) 2008-08-12 2020-01-07 Orpha Swiss Gmbh Forma de administración farmacéutica que contiene tetrahidrobiopterina
CN107011345A (zh) 2008-12-23 2017-08-04 勃林格殷格翰国际有限公司 有机化合物的盐形式
CA2771432A1 (fr) 2009-08-20 2011-02-24 Novartis Ag Composes d'oximes heterocycliques
EP2562176B1 (fr) 2010-04-22 2018-08-15 Nihon University Agent médicinal et boisson/aliment pour prévenir un dysfonctionnement cérébral et améliorer ses symptômes
US9884909B2 (en) * 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
CN103458900A (zh) 2011-03-01 2013-12-18 鲁必康研究私人有限公司 四氢生物蝶呤的稳定组合物
US9216178B2 (en) * 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
US9181254B2 (en) * 2012-05-07 2015-11-10 Shiratori Pharmaceutical Co., Ltd. Method for producing sepiapterin and tetrahydrolactoylpterin
AU2017286544B2 (en) 2016-06-13 2022-10-20 Meharry Medical College Modulation of the nitric oxide synthase pathway for oral health
EP3490536A1 (fr) 2016-07-29 2019-06-05 Dipharma S.A. Trousse de composition pharmaceutique comprenant du dichlorhydrate de saproptérine
CN110312721A (zh) 2016-11-29 2019-10-08 显莎制药公司 墨蝶呤的多晶型物
EP3548497A4 (fr) 2016-11-29 2020-09-02 Censa Pharmaceuticals Inc. Polymorphes de sépiaptérine et leurs sels
TWI765936B (zh) 2016-11-29 2022-06-01 美商東京威力科創Ｆｓｉ股份有限公司 用以對處理腔室中之微電子基板進行處理的平移與旋轉夾頭
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
EP3675863A4 (fr) 2017-09-01 2021-01-27 PTC Therapeutics MP, Inc. Composition pharmaceutique comprenant de la sépiaptérine et ses utilisations
BR112020024329A2 (pt) 2018-05-30 2021-02-23 Ptc Therapeutics Mp, Inc. composições e métodos para aumentar exposição de plasma de tetra-hidrobiopterin
MD3801536T2 (ro) 2018-05-30 2024-11-30 Ptc Therapeutics Mp Inc Administrarea sepiapterinei fără alimente pentru utilizare într-o metodă de creștere a expunerii plasmatice a sepiapterinei
EP3807279B1 (fr) 2018-05-30 2025-12-31 PTC Therapeutics MP, Inc. Sels pharmaceutiquement acceptables de sépiaptérine avec une stabilité améliorée
FI4009978T3 (fi) 2019-08-05 2024-11-01 Ptc Therapeutics Mp Inc Sepiapteriiinin ja sen metaboliittien käyttö säteilyaltistuksen hoitoon
US20220362249A1 (en) 2019-09-25 2022-11-17 Ptc Therapeutics Mp, Inc. Methods for treating hyperphenylalaninemia

Also Published As

Publication number Publication date
JP2020500931A (ja) 2020-01-16
WO2018102314A1 (fr) 2018-06-07
EP3548487A1 (fr) 2019-10-09
US12325706B2 (en) 2025-06-10
EP3548487A4 (fr) 2020-04-29
CN110312721A (zh) 2019-10-08
US20220081443A1 (en) 2022-03-17
JP7148532B2 (ja) 2022-10-05
US20200010469A1 (en) 2020-01-09
CA3043499A1 (fr) 2018-06-07
MX2019006207A (es) 2019-11-18
US11130760B2 (en) 2021-09-28
MX391156B (es) 2025-03-21

Similar Documents

Publication Publication Date Title
MA46972A (fr) Forme polymorphe de sépiaptérine
IL292245A (en) Polymorphic forms of rad1901-2hcl
PT3687999T (pt) Derivados de rapamicina
IL264143B (en) Processes for preparing olaparib
EP3420388A4 (fr) Égalisation de pupille
EP3337383A4 (fr) Estimation de forme de paupière
EP3509581A4 (fr) Formulations de (r
HUE059158T2 (hu) Eljárás pridopidin elõállítására
IL267530A (en) Polymorphs
PT3457851T (pt) Derivados de sobetiroma
EP3668876A4 (fr) Forme polymorphe de tg02
DK3558961T3 (da) Polymorfer
PT4039675T (pt) Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenilo
EP3430073A4 (fr) Composition de polyaryléthercétone
EP3426159A4 (fr) Identification de structures anatomiques
FR3023290B1 (fr) Derives de flavaglines
DK3728208T3 (da) Polymorfer
EP3390422A4 (fr) Formes cristallines de lnt
DK3430004T3 (da) Faststofformer af nilotinibsalte
MA46266A (fr) Formes cristallines
DK3515454T3 (da) Krystallinsk polymorf form af 3-hydroxy-4,5-bis-benzyloxy-6-benzyloxymethyl-2-phenyl-2-oxo-2lambda5-[1,2]oxaphosphinan
EP3473373A4 (fr) Composition de brasure
IL271388B (en) Improved process for preparing imetelstat
EP3529385A4 (fr) Composition de cermet
EP3395819A4 (fr) Forme cristalline de dérivé aminopyrane substitué